The Hidden Struggle: Premenstrual Depression its Impact on Women’s Health and Management Strategies: A Narrative Review.

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 3 | 01 | Page :
    By

    Deepika SN,

  • Syeda Farha S 1 *,

  1. , Department of Nutrition and Dietetics, JSS Academy of Higher Education and Research,, Mysore, India
  2. Assistant Professor,, Department of Nutrition and Dietetics, JSS Academy of Higher Education and Research,, Mysore, India

Abstract

Background: Premenstrual depression, including Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD), represents a significant yet underrecognized contributor to women’s mental health burden. Hormonal fluctuations during the luteal phase interact with neurotransmitter systems, particularly serotonin and GABA, leading to affective and somatic symptoms that impair daily functioning.
Objective: This systematic review synthesizes evidence on the prevalence, pathophysiology, psychological impact, and management strategies of premenstrual depression among reproductive-aged women, with particular emphasis on Indian populations.
Methods: A systematic search of electronic databases, including PubMed, Google Scholar, ScienceDirect, Springer, and related peer-reviewed sources was conducted for studies published between 2015 and 2024. Eligible studies included cross-sectional studies, randomized controlled trials, systematic reviews, and meta-analyses focusing on women aged 20–40 years. Outcomes assessed included depression, anxiety, stress, nutritional status, symptom severity, and therapeutic interventions. Studies involving menopausal women or conducted outside defined criteria were excluded.
Results: Reported prevalence of PMS in India ranged from 14.3% to 74.4%, while PMDD prevalence varied from 3.7% to 65.7%. Evidence indicates strong associations between hormonal sensitivity, serotonergic dysfunction, and mood disturbances. Premenstrual depression significantly affects work productivity, academic performance, sleep quality, and overall quality of life. Non-pharmacological interventions—including dietary modification, calcium and omega-3 supplementation, exercise, and yoga—demonstrated symptom reduction. Selective serotonin reuptake inhibitors (SSRIs) remain the gold-standard pharmacological treatment, with additional benefits observed from hormonal therapies.
Conclusion: Premenstrual depression substantially impacts women’s psychological and functional well-being. Early diagnosis and individualized, multimodal treatment approaches are essential to improve outcomes and reduce disease burden.

Keywords: Premenstrual depression symptoms, premenstrual syndrome, serotonin imbalance, SSRIs, mental health interventions.

How to cite this article:
Deepika SN, Syeda Farha S 1 *. The Hidden Struggle: Premenstrual Depression its Impact on Women’s Health and Management Strategies: A Narrative Review.. International Journal of Nutritions. 2026; 03(01):-.
How to cite this URL:
Deepika SN, Syeda Farha S 1 *. The Hidden Struggle: Premenstrual Depression its Impact on Women’s Health and Management Strategies: A Narrative Review.. International Journal of Nutritions. 2026; 03(01):-. Available from: https://journals.stmjournals.com/ijn/article=2026/view=239917


References

  1. Thanha F, Aysha, Basheer R, Kolar R. Correlation between the pre and post menstrual symptoms and body mass index among females aged between 18–25 years. Int J Sci Healthc Res. 2024;9:19–28. doi:10.52403/ijshr.20240105
  2. Dickerson LM, Mazyck PJ, Hunter MH. Premenstrual syndrome. Am Fam Physician. 2003;67(8):1743–1752.
  3. Parmar P, Deshpande S. Assessment of premenstrual symptoms among adolescent school girls of Mehsana city: a cross-sectional study. Asian J Pharm Clin Res. 2023;16(10):191–195. doi:10.22159/ajpcr.2023.v16i10.48943
  4. Abdul-Razzak K, Alshdaifat E, Sindiani A, Alkhatatbeh M. Severity of premenstrual symptoms among women with musculoskeletal pain: relation to vitamin D, calcium, and psychological symptoms. J Med Life. 2024;17:397–405. doi:10.25122/jml-2023-0050
  5. Balew Zeleke YW, Melese A, et al. Premenstrual syndrome, lifestyle and behavioral coping mechanisms and associated factors among public high school female students in Bahir Dar City, Northwest Ethiopia. Res Sq [Preprint]. 2023. doi:10.21203/rs.3.rs-2418487/v1
  6. Emi Grace R, Rani D. Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) among 10 to 30 year old unmarried Indian girls. 2021;3:2582–5208.
  7. Dutta A, Sharma A. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in India: a systematic review and meta-analysis. Health Promot Perspect. 2021;11(2):161–170. doi:10.34172/hpp.2021.20
  8. Carlini SV, Lanza di Scalea T, McNally ST, Lester J, Deligiannidis KM. Management of premenstrual dysphoric disorder: a scoping review. Int J Womens Health. 2022;14:1783–1801. doi:10.2147/IJWH.S297062
  9. Nabeh OA. New insights on the impact of gut microbiota on premenstrual disorders: will probiotics solve this mystery? Life Sci. 2023;321:121606. doi:10.1016/j.lfs.2023.121606
  10. Premenstrual syndrome and premenstrual dysphoric disorders: a narrative review of etiology, pathophysiology, and diagnosis. Gac Med Caracas. 2022;130. doi:10.47307/GMC.2022.130.3.5
  11. Singh Malik V, Singh V, Kumar H, Kumar S, Kumar K, Behmani R. Menstruation, menstrual distress and mental health: a literature review. 2023;9:6–14.
  12. McPherson ME, Korfine L. Menstruation across time: menarche, menstrual attitudes, experiences, and behaviours. Womens Health Issues. 2004;14(6):193–200. doi:10.1016/j.whi.2004.08.006
  13. Prabhavathi K, Kumar TG, Hemamalini RV, Poornima KN, Saravanan A. Psychological predictors and sleep quality in different grades of premenstrual syndrome. Natl J Physiol Pharm Pharmacol. 2018;8(3):353–357. doi:10.5455/njppp.2017.7.0935427102017
  14. Abu Alwafa R, Badrasawi M, Haj Hamad R. Prevalence of premenstrual syndrome and its association with psychosocial and lifestyle variables: a cross-sectional study from Palestine. BMC Womens Health. 2021;21(1):233. doi:10.1186/s12905-021-01374-6
  15. Fukushima K, Fukushima N, Sato H, Yokota J, Uchida K. Association between nutritional level, menstrual-related symptoms, and mental health in female medical students. PLoS One. 2020;15(7):e0235909.
  16. Sellamuthu H, Kumar A. Impact of premenstrual syndrome on productivity in a pressure cooker manufacturing industry. Physician. 2024;9:1–8. doi:10.38192/1.9.1.4
  17. Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2011;84(8):918–924.
  18. Chang HC, Cheng YC, Yang CH, Tzeng YL, Chen CH. Effects of yoga for coping with premenstrual symptoms in Taiwan: a cluster randomized study. Healthcare (Basel). 2023;11(8):1193. doi:10.3390/healthcare11081193
  19. Frontiers in Psychiatry. Public Mental Health section. 2024;15. doi:10.3389/fpsyt.2024.1363875
  20. Csupor D, Lantos T, Hegyi P, Benkő R, Viola R, Gyöngyi Z, et al. Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomized controlled trials. Complement Ther Med. 2019;47:102190. doi:10.1016/j.ctim.2019.08.024
  21. Khayat S, Fanaei H, Kheirkhah M, Moghadam ZB, Kasaeian A, Javadimehr M. Curcumin attenuates severity of premenstrual syndrome symptoms: a randomized, double-blind, placebo-controlled trial. Complement Ther Med. 2015;23(3):318–324. doi:10.1016/j.ctim.2015.04.001
  22. Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. DARE Database Syst Rev. 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK68709/
  23. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol. 1998;179(2):444–452. doi:10.1016/S0002-9378(98)70382-1
  24. Hsiao MC, Liu CY. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry Clin Neurosci. 2003;57(3):317–321. doi:10.1046/j.1440-1819.2003.01123.x
  25. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106(3):492–501.
  26. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol. 1994;84(5):779–786.
  27. Nazari H, Yari F, Jariani M, Marzban A, Birgandy M. Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine. Arch Gynecol Obstet. 2013;287(3):469–472.
  28. Jackson C, Pearson B, Girdler S, Johnson J, Hamer RM, Killenberg S, Meltzer-Brody S. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD. Hum Psychopharmacol. 2015;30(6):425–434.
Ahead of Print Subscription Review Article
Volume 03
01
Received 17/04/2025
Accepted 02/08/2025
Published 25/02/2026
Publication Time 314 Days
56

Login


My IP

PlumX Metrics